Japanese drug major Astellas Pharma (TYO: 4503) has announced a new research collaboration with Kyoto University to facilitate drug discovery, with a particular focus on biomarkers and “intractable and rare diseases.”
The Alliance Station, or A-Station, will be a new open innovation scheme where clinical and basic research of the university and drug discovery research from the company are closely linked.
The company says it will conduct joint research projects with Kyoto University in all therapeutic areas.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze